Skip to main content

Unicycive Therapeutics, Inc.

UNCY
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001766140

No open-market purchases or sales by Unicycive Therapeutics, Inc. insiders were filed in the last 90 days; 79 institutions reported holding it in 13F filings for Q2 2026, worth $54.6M in total; no superinvestor holds it.

13F holders, Q4 2022

Institutional positions in Unicycive Therapeutics, Inc. as of Dec 31, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works

Institutional holders
9
−3 vs. Q3 2022
Shares held
795.3K
−173.0K (−17.9%) vs. Q3 2022
Total value
$428.3K
−$142.7K (−25.0%) vs. Q3 2022
New holders
2
1 more added
Sold out
5
2 more reduced

Compare with Q3 2022: new holders, sold out and not filed yet

Holders and value by quarter

Institutions reporting UNCY on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.

Institutional holdersQ4 2022: 9 institutions
Q1 2021: 0 institutionsQ2 2021: 0 institutionsQ3 2021: 10 institutionsQ4 2021: 12 institutionsQ1 2022: 12 institutionsQ2 2022: 15 institutionsQ3 2022: 12 institutionsQ4 2022: 9 institutionsQ1 2023: 13 institutionsQ2 2023: 15 institutionsQ3 2023: 16 institutionsQ4 2023: 16 institutionsQ1 2024: 23 institutionsQ2 2024: 24 institutionsQ3 2024: 29 institutionsQ4 2024: 31 institutionsQ1 2025: 29 institutionsQ2 2025: 20 institutionsQ3 2025: 30 institutionsQ4 2025: 35 institutionsQ1 2026: 51 institutionsQ2 2026: 79 institutions
Value heldQ4 2022: $428.3K
Q1 2021: $0Q2 2021: $0Q3 2021: $3.02MQ4 2021: $2.30MQ1 2022: $1.48MQ2 2022: $992.0KQ3 2022: $571.0KQ4 2022: $428.3KQ1 2023: $3.54MQ2 2023: $1.38MQ3 2023: $12.2MQ4 2023: $11.3MQ1 2024: $31.6MQ2 2024: $9.52MQ3 2024: $19.1MQ4 2024: $49.0MQ1 2025: $34.5MQ2 2025: $24.6MQ3 2025: $27.4MQ4 2025: $47.5MQ1 2026: $65.2MQ2 2026: $54.6M
Institutions holding UNCY and their total value by quarter
QuarterHoldersValue
Q2 202679$54.6M
Q1 202651$65.2M
Q4 202535$47.5M
Q3 202530$27.4M
Q2 202520$24.6M
Q1 202529$34.5M
Q4 202431$49.0M
Q3 202429$19.1M
Q2 202424$9.52M
Q1 202423$31.6M
Q4 202316$11.3M
Q3 202316$12.2M
Q2 202315$1.38M
Q1 202313$3.54M
Q4 20229$428.3K
Q3 202212$571.0K
Q2 202215$992.0K
Q1 202212$1.48M
Q4 202112$2.30M
Q3 202110$3.02M
Q2 20210$0
Q1 20210$0

Institutions, Q4 2022

Shares, value and share of portfolio for each institution holding Unicycive Therapeutics, Inc.; share changes are against Q3 2022.

Institutions holding UNCY in Q4 2022
InstitutionSharesValue% of portfolioChange in sharesAction
Nantahala Capital Management, LLC647,416$349.6K0.03%−63,126−8.9%Reduced
Board of Trustees of The Leland Stanford Junior University63,019$34.0K0.00%00.0%Unchanged
Geode Capital Management, LLC26,109$13.0K0.00%00.0%Unchanged
Vanguard Group Inc22,695$12.3K0.00%00.0%Unchanged
Tandem Capital Management Corp15,500$8.37K0.01%00.0%Unchanged
Virtu Financial LLC15,462$8.00K0.00%+15,462New
Tower Research Capital LLC (TRC)4,996$3.00K0.00%−181−3.5%Reduced
Wells Fargo & Company46$250.00%+1+2.2%Added
Bank of America Corp10$50.00%+10New
Ayrton Capital LLC0$00.00%−76,645−100.0%Sold out
Captrust Financial Advisors0$00.00%−18,800−100.0%Sold out
FineMark National Bank & Trust0$00.00%−15,625−100.0%Sold out
Renaissance Technologies LLC0$00.00%−12,900−100.0%Sold out
UBS Group AG0$00.00%−1,190−100.0%Sold out